Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin and Radiotherapy in HER2-Expressing MIBC
NCT05912205Phase 2Not yet recruiting
- Start
- Jul 2023
- Primary completion
- Jul 2025
01
Overview
A Phase 2 trial of disitamab vedotin in urothelial carcinoma of the bladder (UC). Planned start Jul 2023; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
urothelial carcinoma of the bladder (UC)
Beyond the preview
Go deeper on NCT05912205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05912205.